Else Munthe

  • Senior technician (Helse Sør-øst)
  • +47 22 78 19 36
 

Publications 2019

Hanes R, Munthe E, Grad I, Han J, Karlsen I, McCormack E, Meza-Zepeda LA, Stratford EW, Myklebost O (2019)
Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma
Cells, 8 (2)
DOI 10.3390/cells8020189, PubMed 30795553

Publications 2018

Gouravan S, Meza-Zepeda LA, Myklebost O, Stratford EW, Munthe E (2018)
Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas
Int J Mol Sci, 19 (4)
DOI 10.3390/ijms19040969, PubMed 29570692

Namløs HM, Boye K, Mishkin SJ, Barøy T, Lorenz S, Bjerkehagen B, Stratford EW, Munthe E, Kudlow BA, Myklebost O, Meza-Zepeda LA (2018)
Noninvasive Detection of ctDNA Reveals Intratumor Heterogeneity and Is Associated with Tumor Burden in Gastrointestinal Stromal Tumor
Mol Cancer Ther, 17 (11), 2473-2480
DOI 10.1158/1535-7163.MCT-18-0174, PubMed 30097488

Publications 2017

Engkvist ME, Stratford EW, Lorenz S, Meza-Zepeda LA, Myklebost O, Munthe E (2017)
Analysis of the miR-34 family functions in breast cancer reveals annotation error of miR-34b
Sci Rep, 7 (1), 9655
DOI 10.1038/s41598-017-10189-1, PubMed 28848235

Serguienko A, Hanes R, Grad I, Wang MY, Myklebost O, Munthe E (2017)
PP2A Regulatory Subunit B55γ is a Gatekeeper of Osteoblast Maturation and Lineage Maintenance
Stem Cells Dev, 26 (19), 1375-1383
DOI 10.1089/scd.2017.0129, PubMed 28805158

Publications 2016

Hanes R, Grad I, Lorenz S, Stratford EW, Munthe E, Reddy CC, Meza-Zepeda LA, Myklebost O (2016)
Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma
Oncotarget, 7 (34), 54583-54595
DOI 10.18632/oncotarget.10518, PubMed 27409346

Munthe E, Riss PJ, Saga TA, Haraldsen I, Grad I, Bogsrud TV, Bach-Gansmo T (2016)
FDG-based quantitative comparison of glucose metabolism in vitro, exemplified by a head-to-head comparison between a triple-negative breast cancer cell line and a non-malignant foetal cell line
Clin Physiol Funct Imaging, 38 (1), 34-37
DOI 10.1111/cpf.12378, PubMed 27297457

Sandhu V, Wedge DC, Bowitz Lothe IM, Labori KJ, Dentro SC, Buanes T, Skrede ML, Dalsgaard AM, Munthe E, Myklebost O, Lingjærde OC, Børresen-Dale AL, Ikdahl T, Van Loo P, Nord S, Kure EH (2016)
The Genomic Landscape of Pancreatic and Periampullary Adenocarcinoma
Cancer Res, 76 (17), 5092-102
DOI 10.1158/0008-5472.CAN-16-0658, PubMed 27488532

Publications 2015

Serguienko A, Grad I, Wennerstrøm AB, Meza-Zepeda LA, Thiede B, Stratford EW, Myklebost O, Munthe E (2015)
Metabolic reprogramming of metastatic breast cancer and melanoma by let-7a microRNA
Oncotarget, 6 (4), 2451-65
DOI 10.18632/oncotarget.3235, PubMed 25669981

Publications 2014

Wennerström AB, Lothe IM, Sandhu V, Kure EH, Myklebost O, Munthe E (2014)
Generation and characterisation of novel pancreatic adenocarcinoma xenograft models and corresponding primary cell lines
PLoS One, 9 (8), e103873
DOI 10.1371/journal.pone.0103873, PubMed 25148029

Publications 2013

Lauvrak SU, Munthe E, Kresse SH, Stratford EW, Namløs HM, Meza-Zepeda LA, Myklebost O (2013)
Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes
Br J Cancer, 109 (8), 2228-36
DOI 10.1038/bjc.2013.549, PubMed 24064976

Stratford EW, Daffinrud J, Munthe E, Castro R, Waaler J, Krauss S, Myklebost O (2013)
The tankyrase-specific inhibitor JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines
Cancer Med, 3 (1), 36-46
DOI 10.1002/cam4.170, PubMed 24403055

Wang P, Gao Q, Suo Z, Munthe E, Solberg S, Ma L, Wang M, Westerdaal NA, Kvalheim G, Gaudernack G (2013)
Identification and characterization of cells with cancer stem cell properties in human primary lung cancer cell lines
PLoS One, 8 (3), e57020
DOI 10.1371/journal.pone.0057020, PubMed 23469181

Publications 2012

Stratford EW, Castro R, Daffinrud J, Skårn M, Lauvrak S, Munthe E, Myklebost O (2012)
Characterization of liposarcoma cell lines for preclinical and biological studies
Sarcoma, 2012, 148614
DOI 10.1155/2012/148614, PubMed 22911243

Publications 2011

Stratford EW, Castro R, Wennerstrom A, Holm R, Munthe E, Lauvrak S, Bjerkehagen B, Myklebost O (2011)
Liposarcoma Cells with Aldefluor and CD133 Activity have a Cancer Stem Cell Potential
Clin Sarcoma Res, 1 (1), 8
DOI 10.1186/2045-3329-1-8, PubMed 22612877

Publications 2009

Stronen E, Abrahamsen IW, Gaudernack G, Wälchli S, Munthe E, Buus S, Johansen FE, Lund-Johansen F, Olweus J (2009)
Dendritic cells engineered to express defined allo-HLA peptide complexes induce antigen-specific cytotoxic T cells efficiently killing tumour cells
Scand J Immunol, 69 (4), 319-28
DOI 10.1111/j.1365-3083.2008.02223.x, PubMed 19284496

Publications 2008

Døsen-Dahl G, Munthe E, Nygren MK, Stubberud H, Hystad ME, Rian E (2008)
Bone marrow stroma cells regulate TIEG1 expression in acute lymphoblastic leukemia cells: role of TGFbeta/BMP-6 and TIEG1 in chemotherapy escape
Int J Cancer, 123 (12), 2759-66
DOI 10.1002/ijc.23833, PubMed 18798273

Nygren MK, Døsen-Dahl G, Stubberud H, Wälchli S, Munthe E, Rian E (2008)
beta-catenin is involved in N-cadherin-dependent adhesion, but not in canonical Wnt signaling in E2A-PBX1-positive B acute lymphoblastic leukemia cells
Exp Hematol, 37 (2), 225-33
DOI 10.1016/j.exphem.2008.10.007, PubMed 19101069

Publications 2007

Hystad ME, Myklebust JH, Bø TH, Sivertsen EA, Rian E, Forfang L, Munthe E, Rosenwald A, Chiorazzi M, Jonassen I, Staudt LM, Smeland EB (2007)
Characterization of early stages of human B cell development by gene expression profiling
J Immunol, 179 (6), 3662-71
DOI 10.4049/jimmunol.179.6.3662, PubMed 17785802

Publications 2004

Finne EF, Munthe E, Aasheim HC (2004)
A new ephrin-A1 isoform (ephrin-A1b) with altered receptor binding properties abrogates the cleavage of ephrin-A1a
Biochem J, 379 (Pt 1), 39-46
DOI 10.1042/BJ20031619, PubMed 14692877

Munthe E, Finne EF, Aasheim HC (2004)
Expression and functional effects of Eph receptor tyrosine kinase A family members on Langerhans like dendritic cells
BMC Immunol, 5, 9
DOI 10.1186/1471-2172-5-9, PubMed 15176971

Publications 2002

Munthe E, Aasheim HC (2002)
Characterization of the human ephrin-A4 promoter
Biochem J, 366 (Pt 2), 447-58
DOI 10.1042/BJ20011693, PubMed 12030849

Patzke S, Lindeskog M, Munthe E, Aasheim HC (2002)
Characterization of a novel human endogenous retrovirus, HERV-H/F, expressed in human leukemia cell lines
Virology, 303 (1), 164-73
DOI 10.1006/viro.2002.1615, PubMed 12482668

Publications 2000

Munthe E, Rian E, Holien T, Rasmussen A, Levy FO, Aasheim H (2000)
Ephrin-B2 is a candidate ligand for the Eph receptor, EphB6
FEBS Lett, 466 (1), 169-74
DOI 10.1016/s0014-5793(99)01793-7, PubMed 10648835

Aasheim HC, Munthe E, Funderud S, Smeland EB, Beiske K, Logtenberg T (2000)
A splice variant of human ephrin-A4 encodes a soluble molecule that is secreted by activated human B lymphocytes
Blood, 95 (1), 221-30
DOI 10.1182/blood.V95.1.221.001k01_221_230, PubMed 10607706

Publications 1998

Spurkland A, Brinchmann JE, Markussen G, Pedeutour F, Munthe E, Lea T, Vartdal F, Aasheim HC (1998)
Molecular cloning of a T cell-specific adapter protein (TSAd) containing an Src homology (SH) 2 domain and putative SH3 and phosphotyrosine binding sites
J Biol Chem, 273 (8), 4539-46
DOI 10.1074/jbc.273.8.4539, PubMed 9468509

Page visits: 543